Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up.

le de Mascarel, I., Bonichon, F., Coindre, J. M., Trojani, M.
Foilsithe 1992

Micrometastases to axillary lymph nodes from invasive lobular carcinoma of breast: detection by immunohistochemistry and prognostic significance.

le Trojani, M., de Mascarel, I., Coindre, J. M., Bonichon, F.
Foilsithe 1987

Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance.

le Trojani, M., de Mascarel, I., Bonichon, F., Coindre, J. M., Delsol, G.
Foilsithe 1987

An immunohistochemical study of pi class glutathione S-transferase expression in normal human tissue.

le Terrier, P., Townsend, A. J., Coindre, J. M., Triche, T. J., Cowan, K. H.
Foilsithe 1990

Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases.

le Soubeyran, I., Quénel, N., Mauriac, L., Durand, M., Bonichon, F., Coindre J-M
Foilsithe 1996

Expression of MDR1/P glycoprotein in human sarcomas.

le Vergier, B., Cany, L., Bonnet, F., Robert, J., de Mascarel, A., Coindre, J. M.
Foilsithe 1993

Prognostic relevance of a novel proliferation marker, Ki-S11, for soft-tissue sarcoma. A multivariate study.

le Rudolph, P., Kellner, U., Chassevent, A., Collin, F., Bonichon, F., Parwaresch, R., Coindre, J. M.
Foilsithe 1997

pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.

le Soubeyran, I., Quénel, N., Coindre, J. M., Bonichon, F., Durand, M., Wafflart, J., Mauriac, L.
Foilsithe 1996

Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.

le MacGrogan, G., Mauriac, L., Durand, M., Bonichon, F., Trojani, M., de Mascarel, I., Coindre, J. M.
Foilsithe 1996

Prognostic variables for the selection of patients with operable soft tissue sarcomas to be considered in adjuvant chemotherapy trials.

le Ravaud, A., Bui, N. B., Coindre, J. M., Lagarde, P., Tramond, P., Bonichon, F., Stöckle, E., Kantor, G., Trojani, M., Chauvergne, J.
Foilsithe 1992

Clear Cell Sarcoma (Malignant Melanoma) of Soft Parts: A Clinicopathologic Study of 52 Cases

le Hocar, O., Le Cesne, A., Berissi, S., Terrier, P., Bonvalot, S., Vanel, D., Auperin, A., Le Pechoux, C., Bui, B., Coindre, J. M., Robert, C.
Foilsithe 2012

GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study

le Italiano, A., Le Cesne, A., Bellera, C., Piperno-Neumann, S., Duffaud, F., Penel, N., Cassier, P., Domont, J., Takebe, N., Kind, M., Coindre, J.-M., Blay, J.-Y., Bui, B.
Foilsithe 2013

DNA topoisomerase IIα expression and the response toprimary chemotherapy in breast cancer

le MacGrogan, G, Rudolph, P, Mascarel, I de, Mauriac, L, Durand, M, Avril, A, Dilhuydy, J M, Robert, J, Mathoulin-Pélissier, S, Picot, V, Floquet, A, Sierankowski, G, Coindre, J M
Foilsithe 2003

Prognosis and predictive value of KIT exon 11 deletion in GISTs

le Bachet, J-B, Hostein, I, Le Cesne, A, Brahimi, S, Beauchet, A, Tabone-Eglinger, S, Subra, F, Bui, B, Duffaud, F, Terrier, P, Coindre, J-M, Blay, J-Y, Emile, J-F
Foilsithe 2009

Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002)

le Bugat, R, Bataillard, A, Lesimple, T, Voigt, J J, Culine, S, Lortholary, A, Merrouche, Y, Ganem, G, Kaminsky, M C, Negrier, S, Perol, M, Laforêt, C, Bedossa, P, Bertrand, G, Coindre, J M, Fizazi, K
Foilsithe 2003

Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas

le Brahmi, M., Lesluyes, T., Dufresne, A., Toulmonde, M., Italiano, A., Mir, O., Le Cesne, A., Valentin, T., Chevreau, C., Bonvalot, S., Penel, N., Coindre, J.-M., Le Guellec, S., Le Loarer, F., Karanian, M., Blay, J.-Y., Chibon, F.
Foilsithe in ESMO Open (2021)

High frequency of β-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management

le Dômont, J, Salas, S, Lacroix, L, Brouste, V, Saulnier, P, Terrier, P, Ranchère, D, Neuville, A, Leroux, A, Guillou, L, Sciot, R, Collin, F, Dufresne, A, Blay, J-Y, Le Cesne, A, Coindre, J-M, Bonvalot, S, Bénard, J
Foilsithe 2010

Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions

le Ray-Coquard, I., Montesco, M. C., Coindre, J. M., Dei Tos, A. P., Lurkin, A., Ranchère-Vince, D., Vecchiato, A., Decouvelaere, A. V., Mathoulin-Pélissier, S., Albert, S., Cousin, P., Cellier, D., Toffolatti, L., Rossi, C. R., Blay, J. Y.
Foilsithe 2012

Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma

le Dufresne, A., Lesluyes, T., Ménétrier-Caux, C., Brahmi, M., Darbo, E., Toulmonde, M., Italiano, A., Mir, O., Le Cesne, A., Le Guellec, S., Valentin, T., Chevreau, C., Bonvalot, S., Robin, Y.M., Coindre, J-M, Caux, C., Blay, J.Y., Chibon, F.
Foilsithe in Oncoimmunology (2020)

Adherence to consensus-based diagnosis and treatment guidelines in adult soft-tissue sarcoma patients: a French prospective population-based study(†)

le Mathoulin-Pélissier, S., Chevreau, C., Bellera, C., Bauvin, E., Savès, M., Grosclaude, P., Albert, S., Goddard, J., Le Guellec, S., Delannes, M., Bui, B. N., Mendiboure, J., Stoeckle, E., Coindre, J. M., Kantor, G., Kind, M., Cowppli-Bony, A., Hoppe, S., Italiano, A.
Foilsithe 2014